LNTH - Lantheus to discontinue radiotherapy Azedra
2023-08-18 08:43:41 ET
More on Lantheus
- Lantheus: Pylarify And Definity Driving Strong Growth
- POINT Biopharma slips after pipeline update
- Lantheus prostate cancer diagnostics recommended for EU approval
- Lantheus soars 15% on Q1 beat, beats Q2 and FY forecast estimates
- Lantheus, POINT Biopharma receive FDA Fast Track status for prostate cancer candidate
- Seeking Alpha’s Quant Rating on Lantheus
For further details see:
Lantheus to discontinue radiotherapy Azedra